Antiplatelet agents and arterial thrombosis

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

It seems justified and reasonable to prescribe low-dose aspirin for all geriatric patients, and for patients with peripheral arterial disease, clopidogrel for primary prevention. There is, at present, no place for the addition of dipyridamole or oral GPIIb-IIIa antagonists. GPIIb-IIIa antagonists may be indicated in acute events, requiring intervention. Whether patients should be screened for aspirin tolerance or resistance is not clear, but it may be prudent to place patients who fail therapy on a second antiplatelet agent, such as clopidogrel. There is no evidence to suggest that the increase in bleeding that may occur in the elderly should suggest that therapy be withheld and, indeed, there is some evidence that the elderly may derive a relatively increased benefit from the use of these antiplatelet agents.

Original languageEnglish (US)
Pages (from-to)57-74
Number of pages18
JournalClinics in Geriatric Medicine
Volume22
Issue number1
DOIs
StatePublished - Feb 2006

Fingerprint

clopidogrel
Platelet Aggregation Inhibitors
Thrombosis
Aspirin
Dipyridamole
Peripheral Arterial Disease
Primary Prevention
Geriatrics
Hemorrhage
Therapeutics

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Cite this

Antiplatelet agents and arterial thrombosis. / Billett, Henny H.

In: Clinics in Geriatric Medicine, Vol. 22, No. 1, 02.2006, p. 57-74.

Research output: Contribution to journalArticle

@article{70519178da0e48d894877aa94300c781,
title = "Antiplatelet agents and arterial thrombosis",
abstract = "It seems justified and reasonable to prescribe low-dose aspirin for all geriatric patients, and for patients with peripheral arterial disease, clopidogrel for primary prevention. There is, at present, no place for the addition of dipyridamole or oral GPIIb-IIIa antagonists. GPIIb-IIIa antagonists may be indicated in acute events, requiring intervention. Whether patients should be screened for aspirin tolerance or resistance is not clear, but it may be prudent to place patients who fail therapy on a second antiplatelet agent, such as clopidogrel. There is no evidence to suggest that the increase in bleeding that may occur in the elderly should suggest that therapy be withheld and, indeed, there is some evidence that the elderly may derive a relatively increased benefit from the use of these antiplatelet agents.",
author = "Billett, {Henny H.}",
year = "2006",
month = "2",
doi = "10.1016/j.cger.2005.09.002",
language = "English (US)",
volume = "22",
pages = "57--74",
journal = "Clinics in Geriatric Medicine",
issn = "0749-0690",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Antiplatelet agents and arterial thrombosis

AU - Billett, Henny H.

PY - 2006/2

Y1 - 2006/2

N2 - It seems justified and reasonable to prescribe low-dose aspirin for all geriatric patients, and for patients with peripheral arterial disease, clopidogrel for primary prevention. There is, at present, no place for the addition of dipyridamole or oral GPIIb-IIIa antagonists. GPIIb-IIIa antagonists may be indicated in acute events, requiring intervention. Whether patients should be screened for aspirin tolerance or resistance is not clear, but it may be prudent to place patients who fail therapy on a second antiplatelet agent, such as clopidogrel. There is no evidence to suggest that the increase in bleeding that may occur in the elderly should suggest that therapy be withheld and, indeed, there is some evidence that the elderly may derive a relatively increased benefit from the use of these antiplatelet agents.

AB - It seems justified and reasonable to prescribe low-dose aspirin for all geriatric patients, and for patients with peripheral arterial disease, clopidogrel for primary prevention. There is, at present, no place for the addition of dipyridamole or oral GPIIb-IIIa antagonists. GPIIb-IIIa antagonists may be indicated in acute events, requiring intervention. Whether patients should be screened for aspirin tolerance or resistance is not clear, but it may be prudent to place patients who fail therapy on a second antiplatelet agent, such as clopidogrel. There is no evidence to suggest that the increase in bleeding that may occur in the elderly should suggest that therapy be withheld and, indeed, there is some evidence that the elderly may derive a relatively increased benefit from the use of these antiplatelet agents.

UR - http://www.scopus.com/inward/record.url?scp=29244452092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29244452092&partnerID=8YFLogxK

U2 - 10.1016/j.cger.2005.09.002

DO - 10.1016/j.cger.2005.09.002

M3 - Article

VL - 22

SP - 57

EP - 74

JO - Clinics in Geriatric Medicine

JF - Clinics in Geriatric Medicine

SN - 0749-0690

IS - 1

ER -